Esperion Therapeutics, Inc. (0IIM.L)
USD 1.04
(2.97%)
USD 1.04
(2.97%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -209.24 Million USD | 27.3% |
| 2022 | -287.81 Million USD | 9.73% |
| 2021 | -318.82 Million USD | -91.84% |
| 2020 | -166.18 Million USD | -52.44% |
| 2019 | -109.02 Million USD | 45.98% |
| 2018 | -201.81 Million USD | -20.85% |
| 2017 | -166.98 Million USD | -122.72% |
| 2016 | -74.97 Million USD | -50.61% |
| 2015 | -49.78 Million USD | -36.86% |
| 2014 | -36.37 Million USD | -39.43% |
| 2013 | -26.08 Million USD | -122.18% |
| 2012 | -11.74 Million USD | -8.55% |
| 2011 | -10.81 Million USD | 0.0% |
| 2002 | -28.72 Million USD | -15.22% |
| 2001 | -24.93 Million USD | 9.59% |
| 2000 | -27.57 Million USD | -158.44% |
| 1999 | -10.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -61.92 Million USD | -201.48% |
| 2024 Q1 | 61.02 Million USD | 208.3% |
| 2023 FY | -209.24 Million USD | 27.3% |
| 2023 Q4 | -56.34 Million USD | -36.59% |
| 2023 Q2 | -49.93 Million USD | 44.03% |
| 2023 Q1 | -89.22 Million USD | -30.32% |
| 2023 Q3 | -41.25 Million USD | 17.39% |
| 2022 Q4 | -68.46 Million USD | 0.22% |
| 2022 Q3 | -68.61 Million USD | 14.53% |
| 2022 Q2 | -80.27 Million USD | -13.9% |
| 2022 Q1 | -70.47 Million USD | -8.22% |
| 2022 FY | -287.81 Million USD | 9.73% |
| 2021 Q4 | -65.11 Million USD | 6.15% |
| 2021 Q3 | -69.38 Million USD | -58.89% |
| 2021 FY | -318.82 Million USD | -91.84% |
| 2021 Q1 | -90.93 Million USD | 12.96% |
| 2021 Q2 | -43.66 Million USD | 51.98% |
| 2020 Q2 | 124.61 Million USD | 259.25% |
| 2020 FY | -166.18 Million USD | -52.44% |
| 2020 Q1 | -78.24 Million USD | -26.32% |
| 2020 Q3 | -85.43 Million USD | -168.56% |
| 2020 Q4 | -104.47 Million USD | -22.28% |
| 2019 Q4 | -61.94 Million USD | 9.41% |
| 2019 FY | -109.02 Million USD | 45.98% |
| 2019 Q1 | 87.37 Million USD | 245.54% |
| 2019 Q2 | -54.22 Million USD | -162.05% |
| 2019 Q3 | -68.37 Million USD | -26.11% |
| 2018 Q3 | -49.91 Million USD | -9.14% |
| 2018 Q4 | -60.03 Million USD | -20.29% |
| 2018 FY | -201.81 Million USD | -20.85% |
| 2018 Q1 | -46.13 Million USD | -21.74% |
| 2018 Q2 | -45.73 Million USD | 0.87% |
| 2017 Q2 | -43.33 Million USD | -6.9% |
| 2017 Q1 | -40.54 Million USD | -40.01% |
| 2017 Q3 | -45.21 Million USD | -4.34% |
| 2017 FY | -166.98 Million USD | -122.72% |
| 2017 Q4 | -37.89 Million USD | 16.21% |
| 2016 FY | -74.97 Million USD | -50.61% |
| 2016 Q2 | -14.03 Million USD | 3.77% |
| 2016 Q1 | -14.58 Million USD | -11.15% |
| 2016 Q3 | -17.4 Million USD | -23.99% |
| 2016 Q4 | -28.95 Million USD | -66.39% |
| 2015 Q3 | -12.8 Million USD | -3.28% |
| 2015 Q4 | -13.12 Million USD | -2.51% |
| 2015 Q1 | -11.46 Million USD | -21.24% |
| 2015 Q2 | -12.39 Million USD | -8.1% |
| 2015 FY | -49.78 Million USD | -36.86% |
| 2014 Q3 | -9.8 Million USD | -6.15% |
| 2014 Q4 | -9.45 Million USD | 3.56% |
| 2014 Q2 | -9.23 Million USD | -17.32% |
| 2014 Q1 | -7.87 Million USD | 18.74% |
| 2014 FY | -36.37 Million USD | -39.43% |
| 2013 Q2 | -6.92 Million USD | -63.26% |
| 2013 Q1 | -4.23 Million USD | -52.74% |
| 2013 Q4 | -9.68 Million USD | -84.97% |
| 2013 Q3 | -5.23 Million USD | 24.31% |
| 2013 FY | -26.08 Million USD | -122.18% |
| 2012 FY | -11.74 Million USD | -8.55% |
| 2012 Q3 | -3.35 Million USD | -5.85% |
| 2012 Q2 | -3.16 Million USD | -29.29% |
| 2012 Q1 | -2.44 Million USD | 0.0% |
| 2012 Q4 | -2.77 Million USD | 17.19% |
| 2011 FY | -10.81 Million USD | 0.0% |
| 2003 Q3 | -6.56 Million USD | 22.19% |
| 2003 Q2 | -8.43 Million USD | -13.89% |
| 2003 Q1 | -7.4 Million USD | -11.89% |
| 2002 FY | -28.72 Million USD | -15.22% |
| 2002 Q4 | -6.61 Million USD | 5.17% |
| 2002 Q3 | -6.98 Million USD | 10.79% |
| 2002 Q2 | -7.82 Million USD | -7.13% |
| 2002 Q1 | -7.3 Million USD | -15.12% |
| 2001 Q2 | -6.32 Million USD | -5.75% |
| 2001 Q1 | -5.98 Million USD | -7.48% |
| 2001 FY | -24.93 Million USD | 9.59% |
| 2001 Q4 | -6.34 Million USD | -1.0% |
| 2001 Q3 | -6.28 Million USD | 0.7% |
| 2000 Q2 | -6.51 Million USD | -38.8% |
| 2000 Q1 | -4.69 Million USD | 0.0% |
| 2000 Q4 | -5.56 Million USD | 48.49% |
| 2000 FY | -27.57 Million USD | -158.44% |
| 2000 Q3 | -10.8 Million USD | -65.86% |
| 1999 FY | -10.67 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -36.568% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3175.129% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -76.561% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.577% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 16000.304% |
| Perrigo Company plc | -12.7 Million USD | -1547.622% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 24.22% |
| Illumina, Inc. | -1.16 Billion USD | 81.977% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 103.49% |
| Nektar Therapeutics | -276.05 Million USD | 24.201% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 52.876% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 115.409% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -89.264% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -424.957% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 224.816% |
| Waters Corporation | 642.23 Million USD | 132.581% |
| Biogen Inc. | 1.16 Billion USD | 118.022% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 18.843% |
| Adicet Bio, Inc. | -142.65 Million USD | -46.678% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 116.875% |
| Homology Medicines, Inc. | -53.74 Million USD | -289.349% |
| Geron Corporation | -184.12 Million USD | -13.643% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 52.47% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -38.041% |
| Myriad Genetics, Inc. | -112 Million USD | -86.829% |
| Evolus, Inc. | -61.68 Million USD | -239.22% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -340.476% |
| bluebird bio, Inc. | -211.91 Million USD | 1.258% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 56.515% |
| Zoetis Inc. | 2.34 Billion USD | 108.927% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -286.152% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -136.489% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 126.528% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 105.781% |
| uniQure N.V. | -308.47 Million USD | 32.168% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -395.86% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 42.873% |
| Verastem, Inc. | -87.36 Million USD | -139.505% |
| FibroGen, Inc. | -284.23 Million USD | 26.381% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 60.96% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -369.131% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 183.8% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 105.293% |
| OPKO Health, Inc. | -188.86 Million USD | -10.794% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -143.609% |
| Exelixis, Inc. | 207.76 Million USD | 200.714% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 174.308% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 12.536% |
| Imunon, Inc. | -19.51 Million USD | -972.243% |
| Blueprint Medicines Corporation | -506.98 Million USD | 58.727% |
| Insmed Incorporated | -749.56 Million USD | 72.084% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 40.569% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 297.143% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1751.263% |
| Incyte Corporation | 597.59 Million USD | 135.015% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 72.485% |